Under-the-radar penny stocks can be some of the most rewarding investments on the market. Look at ACADIA Pharmaceuticals (NASDAQ:ACAD), for example. Back in 2011, the biotech was just developing its treatment of Parkinson’s disease psychosis and traded at just 70 cents. By 2015, it was at $51.24.Or, look at Advanced Micro Devices (NASDAQ:AMD). In 2015, it traded at about $1.99. Today, thanks to the artificial intelligence and semiconductor boom, it hit a hit of $214.81.Each had incredible growth stories tha ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team operates from key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2] Group 2 - The company specializes in various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [2] - Proactive adopts technology enthusiastically, utilizing decades of expertise and experience among its content creators [2] - Automation and software tools, including generative AI, are occasionally used, but all content is edited and authored by humans [3]

Core Insights - Atossa Therapeutics supports new USPSTF guidelines recommending breast cancer screening for women starting at age 40, addressing rising breast cancer rates and disparities in diagnosis and mortality [1][2][4] Group 1: Guidelines and Impact - The updated guidelines suggest biennial mammography screening for women aged 40 to 74, responding to increased breast cancer rates among younger women and racial disparities [2] - The guidelines are set to take effect ahead of a September 2024 FDA deadline for mammogram facilities to provide detailed breast density information, which is a significant risk factor for breast cancer [2] Group 2: Company Initiatives - Atossa is evaluating its lead asset, (Z)-endoxifen, in five Phase 2 clinical trials, including a study focused on reducing mammographic breast density in premenopausal women [3][6] - The company emphasizes the importance of developing therapies to prevent breast cancer, noting that women with dense breast tissue are five times more likely to develop the disease [4] Group 3: Product Details - (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator (SERM) that not only inhibits estrogen receptors but also degrades them, showing efficacy in patients resistant to other hormonal treatments [5] - Atossa is developing an oral formulation of (Z)-endoxifen that bypasses liver metabolism and stomach acidity, demonstrating good tolerance in early studies [6] Group 4: Company Overview - Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on innovative oncology medicines, particularly in breast cancer prevention and treatment [7]

SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates (ADCs) and (Z)-endoxifen. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The expanded research agreement with Weill Cornell will build ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Insights - Atossa Therapeutics and Quantum Leap Healthcare Collaborative have initiated a study to evaluate the combination of (Z)-endoxifen and abemaciclib in women with ER+/HER2- breast cancer [1][2] - The study aims to enroll approximately 20 women with newly diagnosed invasive breast cancer, focusing on a neoadjuvant treatment approach [1][2] - (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator (SERM) that has shown efficacy in patients resistant to other hormonal treatments [4][5] Company Overview - Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative oncology medicines, particularly for breast cancer [6] - The company is developing a proprietary oral formulation of (Z)-endoxifen that bypasses liver metabolism and stomach acidity to achieve therapeutic concentrations [5] - Atossa's (Z)-endoxifen is protected by three issued U.S. patents and numerous pending applications [5] Study Details - The new study is part of the ongoing I-SPY 2 Endocrine Optimization Pilot Protocol (EOP), targeting patients with ER+ invasive breast cancer who are at high risk for recurrence [2][8] - The study will assess the efficacy of (Z)-endoxifen in combination with abemaciclib, which is a CDK 4/6 inhibitor, to potentially enhance treatment outcomes [3][2] - Data presented at the AACR annual meeting indicated that (Z)-endoxifen can stop the growth of ER+ breast cancer and may shrink or eliminate tumors [3] Collaboration and Goals - Quantum Leap Healthcare Collaborative will conduct the study, with Atossa and Eli Lilly responsible for supplying their respective drugs [3] - The I-SPY TRIALs aim to rapidly screen promising treatments and identify effective options for specific patient subgroups based on molecular characteristics [8]

Atossa Therapeutics, Inc. (ATOS) recently announced promising safety and efficacy data from the company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.(Z)-endoxifen is being assessed as a neoadjuvant treatment for premenopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer as part of the EVANGELINE research.More on the EVANGELINE StudyIn Phase 2 EVANGELINE study, participants are likely to recei ...

Core Viewpoint - Atossa Therapeutics, Inc. is actively engaging with investors through a presentation at the Noble Capital Markets Emerging Growth Healthcare Conference, highlighting its focus on innovative treatments for breast cancer [1][2] Company Overview - Atossa Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative medicines targeting significant unmet medical needs in oncology, particularly breast cancer [2] - The company is focusing on (Z)-endoxifen as a potential treatment and preventive measure for breast cancer [2] Event Details - CEO Steven Quay will present at the conference on April 17, 2024, at 9:00 am ET, with a virtual format available for attendees [1] - The presentation will be accessible for 90 days post-event on Atossa's investor relations page and Channelchek [1]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced promising safety and efficacy data from the Company's Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial. The EVANGELINE study is evaluating (Z)-endoxifen as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage b ...